412 related articles for article (PubMed ID: 26428226)
21. FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.
Liu Y; Qiao F; Leiferman PC; Ross A; Schlenker EH; Wang H
Hum Mol Genet; 2017 Nov; 26(22):4416-4428. PubMed ID: 28973411
[TBL] [Abstract][Full Text] [Related]
22. Generation of induced pluripotent stem cell line, ICGi033-A, by reprogramming peripheral blood mononuclear cells from a patient with Huntington's disease.
Grigor'eva EV; Malakhova AA; Sorogina DA; Pavlova SV; Malankhanova TB; Abramycheva NY; Klyushnikov SA; Illarioshkin SN; Zakian SM
Stem Cell Res; 2022 Aug; 63():102868. PubMed ID: 35872525
[TBL] [Abstract][Full Text] [Related]
23. Concise Review: The Use of Stem Cells for Understanding and Treating Huntington's Disease.
Connor B
Stem Cells; 2018 Feb; 36(2):146-160. PubMed ID: 29178352
[TBL] [Abstract][Full Text] [Related]
24. Induced pluripotent stem cell lines from Huntington's disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway.
Castiglioni V; Onorati M; Rochon C; Cattaneo E
Neurobiol Dis; 2012 Apr; 46(1):30-40. PubMed ID: 22227000
[TBL] [Abstract][Full Text] [Related]
25. Stem cell therapy and cellular engineering for treatment of neuronal dysfunction in Huntington's disease.
Choi KA; Hwang I; Park HS; Oh SI; Kang S; Hong S
Biotechnol J; 2014 Jul; 9(7):882-94. PubMed ID: 24827816
[TBL] [Abstract][Full Text] [Related]
26. Huntington's disease: dancing in a dish.
Zhang K; Yi F; Liu GH; Izpisua Belmonte JC
Cell Res; 2012 Dec; 22(12):1627-30. PubMed ID: 22868272
[TBL] [Abstract][Full Text] [Related]
27. Human-to-mouse prion-like propagation of mutant huntingtin protein.
Jeon I; Cicchetti F; Cisbani G; Lee S; Li E; Bae J; Lee N; Li L; Im W; Kim M; Kim HS; Oh SH; Kim TA; Ko JJ; Aubé B; Oueslati A; Kim YJ; Song J
Acta Neuropathol; 2016 Oct; 132(4):577-92. PubMed ID: 27221146
[TBL] [Abstract][Full Text] [Related]
28. Epigenetics of Huntington's Disease.
Bassi S; Tripathi T; Monziani A; Di Leva F; Biagioli M
Adv Exp Med Biol; 2017; 978():277-299. PubMed ID: 28523552
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic and transcriptional modulation of WDR5, a chromatin remodeling protein, in Huntington's disease human induced pluripotent stem cell (hiPSC) model.
Baronchelli S; La Spada A; Ntai A; Barbieri A; Conforti P; Jotti GS; Redaelli S; Bentivegna A; De Blasio P; Biunno I
Mol Cell Neurosci; 2017 Jul; 82():46-57. PubMed ID: 28476540
[TBL] [Abstract][Full Text] [Related]
30. Advances in huntington disease drug discovery: novel approaches to model disease phenotypes.
Bard J; Wall MD; Lazari O; Arjomand J; Munoz-Sanjuan I
J Biomol Screen; 2014 Feb; 19(2):191-204. PubMed ID: 24196395
[TBL] [Abstract][Full Text] [Related]
31. Induced neural stem cells as a means of treatment in Huntington's disease.
Choi KA; Hong S
Expert Opin Biol Ther; 2017 Nov; 17(11):1333-1343. PubMed ID: 28792249
[TBL] [Abstract][Full Text] [Related]
32. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease.
Joshi AU; Ebert AE; Haileselassie B; Mochly-Rosen D
J Mol Cell Cardiol; 2019 Feb; 127():125-133. PubMed ID: 30550751
[TBL] [Abstract][Full Text] [Related]
33. Use of human stem cells in Huntington disease modeling and translational research.
Golas MM; Sander B
Exp Neurol; 2016 Apr; 278():76-90. PubMed ID: 26826449
[TBL] [Abstract][Full Text] [Related]
34. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity.
Mattis VB; Tom C; Akimov S; Saeedian J; Østergaard ME; Southwell AL; Doty CN; Ornelas L; Sahabian A; Lenaeus L; Mandefro B; Sareen D; Arjomand J; Hayden MR; Ross CA; Svendsen CN
Hum Mol Genet; 2015 Jun; 24(11):3257-71. PubMed ID: 25740845
[TBL] [Abstract][Full Text] [Related]
35. Haplotype-based stratification of Huntington's disease.
Chao MJ; Gillis T; Atwal RS; Mysore JS; Arjomand J; Harold D; Holmans P; Jones L; Orth M; Myers RH; Kwak S; Wheeler VC; MacDonald ME; Gusella JF; Lee JM
Eur J Hum Genet; 2017 Nov; 25(11):1202-1209. PubMed ID: 28832564
[TBL] [Abstract][Full Text] [Related]
36. Brain microvascular endothelial cell dysfunction in an isogenic juvenile iPSC model of Huntington's disease.
Linville RM; Nerenberg RF; Grifno G; Arevalo D; Guo Z; Searson PC
Fluids Barriers CNS; 2022 Jun; 19(1):54. PubMed ID: 35773691
[TBL] [Abstract][Full Text] [Related]
37. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells.
Jeon I; Lee N; Li JY; Park IH; Park KS; Moon J; Shim SH; Choi C; Chang DJ; Kwon J; Oh SH; Shin DA; Kim HS; Do JT; Lee DR; Kim M; Kang KS; Daley GQ; Brundin P; Song J
Stem Cells; 2012 Sep; 30(9):2054-62. PubMed ID: 22628015
[TBL] [Abstract][Full Text] [Related]
38. Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway.
Szlachcic WJ; Switonski PM; Krzyzosiak WJ; Figlerowicz M; Figiel M
Dis Model Mech; 2015 Sep; 8(9):1047-57. PubMed ID: 26092128
[TBL] [Abstract][Full Text] [Related]
39. Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs.
Chiu FL; Lin JT; Chuang CY; Chien T; Chen CM; Chen KH; Hsiao HY; Lin YS; Chern Y; Kuo HC
Hum Mol Genet; 2015 Nov; 24(21):6066-79. PubMed ID: 26264576
[TBL] [Abstract][Full Text] [Related]
40. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y; Deng W
Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
